News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–44
Matches
44
Sources here
7
Companies here
1
Search results Stored financial headlines

Active search

44 matching headlines

Ticker or company: NPCEMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Market update Main company 🇺🇸 United States

NPCE|Neuropace Inc|Price:14.810|Chg%:+0.130

Neuropace Inc. (NPCE) closed at $14.810, up 0.89%. The company specializes in medical devices, particularly its RNS System for treating drug-resistant epilepsy by delivering personalized, real-time treatment at the seizure source. The article also provides company information, executive details including their shareholdings, and institutional …

NPCE main company
Sharemaestro market context Price below Trend Line 52 weeks +64.3% · Next-week setup positive 57.8% NPCE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Mizuho Begins Coverage on NeuroPace (NASDAQ:NPCE)

Mizuho has initiated coverage on NeuroPace (NASDAQ:NPCE) with an "outperform" rating and a $22 price target, representing a potential 50.9% upside. This new rating contributes to a "Moderate Buy" consensus among analysts, despite the company currently being unprofitable. NeuroPace recently exceeded Q1 earnings and …

NPCE main company
Sharemaestro market context Price below Trend Line 52 weeks +64.3% · Next-week setup positive 57.8% NPCE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

Mizuho initiates NeuroPace stock coverage with outperform rating

Mizuho has initiated coverage on NeuroPace Inc. (NASDAQ:NPCE) with an "outperform" rating and a price target of $22.00, representing a 51% upside potential from its current stock price. The rating is driven by findings from a July 2026 neurology survey indicating potential FDA label …

NPCE main company
Sharemaestro market context Price below Trend Line 52 weeks +64.3% · Next-week setup positive 57.8% NPCE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

NeuroPace (NPCE) Proxy filing Summary

This article summarizes NeuroPace's (NPCE) proxy filing from April 21, 2026. Key items include the election of two Class II director nominees, Lisa Andrade and Scott Huennekens, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, …

NPCE main company
Sharemaestro market context Price below Trend Line 52 weeks +64.3% · Next-week setup positive 57.8% NPCE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

(NPCE) Volatility Zones as Tactical Triggers

This article analyzes Neuropace Inc. (NASDAQ: NPCE) using AI models to identify volatility zones and tactical triggers for trading. It highlights a weak near-term sentiment challenging long-term strength, with an exceptional 66.2:1 risk-reward setup targeting a 17.5% gain. The analysis provides three distinct trading …

NPCE main company
Sharemaestro market context Price below Trend Line 52 weeks +64.3% · Next-week setup positive 57.8% NPCE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Market update Main company 🇺🇸 United States

NeuroPace (NPCE) Stock Forum and Discussion

This article provides a discussion forum for NeuroPace (NPCE) stock. It likely includes various forms of content for investors and interested parties to engage with information about the company's financial performance and related news.

NPCE main company
Sharemaestro market context Price below Trend Line 52 weeks +64.3% · Next-week setup positive 57.8% NPCE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

NeuroPace (NPCE) 25th Annual Needham Virtual Healthcare Conference Summary

NeuroPace presented at the 25th Annual Needham Virtual Healthcare Conference, highlighting its mission to transform the lives of epilepsy patients. The company achieved $100 million in revenue in 2025, growing at 25%, and is focused on expanding market penetration and developing new indications and …

NPCE main company
Sharemaestro market context Price below Trend Line 52 weeks +64.3% · Next-week setup positive 57.8% NPCE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NeuroPace (NPCE) stock is recommended for retention due to anticipated growth from its RNS System adoption, expanding referral networks, and AI innovations, with potential long-term benefits from an IGE indication. However, profitability may face near-term pressure from increased investments and seasonality, and the IGE …

NPCE main company
Sharemaestro market context Price below Trend Line 52 weeks +64.3% · Next-week setup positive 57.8% NPCE stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context